Fig. 2

Loss of IRF2 reduces the expression of MHC I pathway components in a primary human melanoma. A Diagram of gene editing of a human patient melanoma (AV17) from passage in NSG mice. After editing, NSG mice were injected s.c. with WT and IRF2KO tumors, and once the tumors were palpable, they were harvested and analyzed for: B the expression of MHC I and PDL1 molecules on the tumors was analyzed by flow cytometer (C) mRNA expression of the MHC I pathway components was analyzed by qPCR. Each dot represents a biological replicate. Statistical analysis was calculated by GraphPad Prism, **P < 0.01, ***P < 0.001